Recombinant Human SLAMF7 cell lysate
Cat.No. : | SLAMF7-2378HCL |
Product Overview : | Human SLAMF7 / CRACC / CD319 derived in Human Cells. The whole cell lysate is provided in 1X Sample Buffer.Browse all transfected cell lysate positive controls |
- Specification
- Gene Information
- Related Products
- Download
Source : | Human cells |
Species : | Human |
Preparation method : | Transfected cells were cultured for 48hrs before collection. The cells were lysed in modified RIPA buffer with cocktail of protease inhibitors. Cell debris was removed by centrifugation and then centrifuged to clarify the lysate. The cell lysate was boiled for 5 minutes in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% b-mercaptoethanol, and lyophilized. |
Lysis buffer : | Modified RIPA Lysis Buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF |
Quality control Testing : | 12.5% SDS-PAGE Stained with Coomassie Blue |
Recommended Usage : | 1. Centrifuge the tube for a few seconds and ensure the pellet at the bottom of the tube.2. Re-dissolve the pellet using 200μL pure water and boiled for 2-5 min.3. Store it at -80°C. Recommend to aliquot the cell lysate into smaller quantities for optimal storage. Avoid repeated freeze-thaw cycles.Notes:The lysate is ready to load on SDS-PAGE for Western blot application. If dissociating conditions are required, add reducing agent prior to heating. |
Stability : | Samples are stable for up to twelve months from date of receipt at -80°C |
Storage Buffer : | 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF |
Storage Instruction : | Lysate samples are stable for 12 months from date of receipt when stored at -80°C. Avoid repeated freeze-thaw cycles. Prior to SDS-PAGE fractionation, boil the lysate for 5 minutes. |
Tag : | Non |
Gene Name : | SLAMF7 SLAM family member 7 [ Homo sapiens ] |
Official Symbol : | SLAMF7 |
Synonyms : | SLAMF7; SLAM family member 7; 19A; CD319; CRACC; CS1; protein 19A; CD2 subset 1; 19A24 protein; membrane protein FOAP-12; CD2-like receptor activating cytotoxic cells; CD2-like receptor-activating cytotoxic cells; novel LY9 (lymphocyte antigen 9) like protein; |
Gene ID : | 57823 |
mRNA Refseq : | NM_021181 |
Protein Refseq : | NP_067004 |
MIM : | 606625 |
UniProt ID : | Q9NQ25 |
Chromosome Location : | 1q23.1-q24.1 |
Function : | receptor activity; |
Products Types
◆ Recombinant Protein | ||
SLAMF7-187H | Recombinant Human SLAMF7 protein, His-Avi-tagged, Biotinylated | +Inquiry |
Slamf7-5898M | Recombinant Mouse Slamf7 Protein, Myc/DDK-tagged | +Inquiry |
SLAMF7-294H | Recombinant Human SLAMF7 Protein (ECD), Fc-His-tagged(C-ter) | +Inquiry |
SLAMF7-2328H | Recombinant Human SLAMF7 protein(Met1-Met226), hFc-tagged, Biotinylated | +Inquiry |
SLAMF7-925H | Recombinant Human SLAMF7 protein, mFc-tagged | +Inquiry |
◆ Lysates | ||
SLAMF7-2591MCL | Recombinant Mouse SLAMF7 cell lysate | +Inquiry |
Related Gene
Not For Human Consumption!
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewIt has a high solubility and can be easily prepared at the desired concentration.
It was found to be well active and could effectively perform the required biological activity experiments.
It was observed that SLAMF7 had good crystallinity, which was conducive to crystallography research.
Q&As (6)
Ask a questionSLAMF7 protein is involved in regulating immune cell activation, proliferation, and transmission of background signals by binding to activating ligands, such as CD319, thereby influencing the immune response.
By combining with immunotherapy, such as anti-PD-1 antibodies, the immune response can be further enhanced and the anti-tumor effect can be improved. The study of SLAMF7 protein provides a new direction for the development of combinatorial therapeutic strategies.
This protein is mainly expressed in the immune system, including immune cells such as plasma cells, NK cells, and activated T cells.
The role of SLAMF7 protein in other types of cancer is unclear, and further research is needed to determine its potential role in other cancers.
Yes, the SLAMF7 protein has been shown to be a potential therapeutic target. A monoclonal antibody drug targeting SLAMF7 protein (Elotuzumab) has been developed for the treatment of multiple myeloma.
SLAMF7 protein interacts with NK cells in multiple myeloma and plays a role in inhibiting and controlling tumor growth by activating the anti-tumor activity of NK cells.
Ask a Question for All SLAMF7 Products
Required fields are marked with *
My Review for All SLAMF7 Products
Required fields are marked with *
Inquiry Basket